136 related articles for article (PubMed ID: 23009225)
1. A case of metachronous double primary neuroendocrine cancer in pancreas/ileum and uterine cervix.
Sisti G; Buccoliero AM; Novelli L; Sansovini M; Severi S; Pieralli A; Livi L; Fambrini M
Ups J Med Sci; 2012 Nov; 117(4):453-6. PubMed ID: 23009225
[TBL] [Abstract][Full Text] [Related]
2. Clinical Usefulness of
Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
[TBL] [Abstract][Full Text] [Related]
3. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
Panagiotidis E; Bomanji J
PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers.
Jadvar H
Semin Nucl Med; 2012 Jul; 42(4):247-54. PubMed ID: 22681673
[TBL] [Abstract][Full Text] [Related]
5. Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.
Lorusso M; Inzani F; Castaldi P; Menghi R; Schinzari G; Rindi G; Rufini V
Pancreas; 2018 Apr; 47(4):e20-e22. PubMed ID: 29521949
[No Abstract] [Full Text] [Related]
6. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
7. Can PET/CT guide the personalized treatment of patients with gastroenteropancreatic neuroendocrine neoplasms?
Schillaci O
J Nucl Med; 2014 Nov; 55(11):1757-8. PubMed ID: 25342386
[No Abstract] [Full Text] [Related]
8. A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: case report.
Demirkan B; Unek IT; Eriksson B; Akarsu M; Durak H; Sağol O; Obuz F; Binicier C; Füzün M; Alakavuklar M
Turk J Gastroenterol; 2009 Sep; 20(3):214-9. PubMed ID: 19821205
[TBL] [Abstract][Full Text] [Related]
9. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
10. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
11. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F
Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
Minn H; Kemppainen J; Kauhanen S; Forsback S; Seppänen M
PET Clin; 2014 Jan; 9(1):27-36. PubMed ID: 25029931
[TBL] [Abstract][Full Text] [Related]
13. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
14. [Positron emission tomography with fluorodeoxyglucose in gastro-entero-pancreatic tumors: diagnostic role and prognostic implications].
Pasquali C; Sperti C; Lunardi C; Scappin S; Chierichetti F; Liessi G; Pedrazzoli S
Suppl Tumori; 2005; 4(3):S68-71. PubMed ID: 16437910
[TBL] [Abstract][Full Text] [Related]
15. Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT).
Hofman MS; Michael M; Kashyap R; Hicks RJ
J Nucl Med; 2015 Jun; 56(6):968-9. PubMed ID: 25814516
[No Abstract] [Full Text] [Related]
16. Reply: Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT).
Garin E; Edeline J
J Nucl Med; 2015 Jun; 56(6):969. PubMed ID: 25908828
[No Abstract] [Full Text] [Related]
17. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
[TBL] [Abstract][Full Text] [Related]
18. A rare case with synchronous gastric gastrointestinal stromal tumor, pancreatic neuroendocrine tumor, and uterine leiomyoma.
Arabadzhieva E; Yonkov A; Bonev S; Bulanov D; Taneva I; Vlahova A; Dikov T; Dimitrova V
World J Surg Oncol; 2016 Nov; 14(1):287. PubMed ID: 27846844
[TBL] [Abstract][Full Text] [Related]
19. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
20. Recurrence of Extramedullary Plasmacytomas Involving Lymph Nodes and Pancreas Revealed by 68Ga-DOTATATE and 18F-FDG PET/CT.
Pan Q; Luo Y; Li J; Zhang S; Li F
Clin Nucl Med; 2018 Dec; 43(12):936-938. PubMed ID: 30179917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
